Nithan Narendra, MD
Gastroenterology · Bronx, NYNPI 1457531873
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $83,775 of the $98,693 with a category attached, or 84.9%. AbbVie accounts for 98.8% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $34,232 and has fallen 73.0% since, to $9,256 in 2025. Among gastroenterology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 151 payments — averaging $653.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$97K
- Gilead$468
- Intercept Pharmaceuticals, Inc.$256
- Madrigal Pharmaceuticals$193
- Palette Life Sciences, Inc.$145
- Aurinia Pharma U.S., Inc.$108
- plus $40 from 1 others
What the payments were for
- Speaking & faculty fees$83,77585%
- Travel & lodging$9,77510%
- Food & beverage$5,1285%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 131 | $97,484 |
| Gilead | 9 | $468 |
| Intercept Pharmaceuticals, Inc. | 2 | $256 |
| Madrigal Pharmaceuticals | 4 | $193 |
| Palette Life Sciences, Inc. | 2 | $145 |
| Aurinia Pharma U.S., Inc. | 1 | $108 |
| Intra-sana Laboratories | 2 | $40 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$98,693 in reported general payments places this provider in the 95th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 80 | $3,930 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 46 | $649 |
| Omeprazole | 44 | $178 |
| Pantoprazole Sodium | 30 | $172 |
| Famotidine | 29 | $158 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 11 | $137 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Bronx
- David SteinBronx$196K
- Sammy HoBronx$195K
- Vivek GumasteBronx$139K
- David Carr LockeNew York$2M
- Arthur KornbluthNew York$1.9M
- Maya SrivastavaWilliamsville$1.8M
- Melissa PalmerPlainview$1M
- Sonal KumarNew York$1M
- David PoppersNew York$939K
- Ellen ScherlNew York$857K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.